Oregon Medical Board

BOARD ACTION REPORT

December 15, 2018

The information contained in this report summarizes new, interim, and final actions taken by the Oregon Medical Board between November 16, 2018, and December 15, 2018.

Scanned copies of Interim Stipulated Orders, Orders of Emergency Suspension, Stipulated Orders, Final Orders, Termination Orders, Modification Orders and Voluntary Limitations are included at the end of this report in the order that they appear in the report. These orders are marked with an * asterisk. Scanned copies of Consent Agreements are not posted, as they are not disciplinary action and impose no practice limitations. Complaint and Notices of Proposed Disciplinary Action are not listed in this report, as they are not final actions by the Board. Both Orders, however, are public and are available upon request.

Printed copies of the Board Orders not provided with this report are available to the public. To obtain a printed copy of a Board Order not provided in this report, please complete the License Verification and Malpractice Report Request (http://www.oregon.gov/OMB/ombforms1/request-licensee-info-verification.pdf) found under the Forms link on the Board's web site. Submit it with the \$10.00 fee *per licensee* and mail to:

Oregon Medical Board 1500 SW 1st Ave, Ste 620 Portland, OR 97201

Copies of the Orders listed below are mailed to Oregon hospitals where the Licensee had <u>self-reported</u> that he/she has privileges.

*Douglas, Ben Harold, II, MD; MD19528; Tillamook, OR

On November 20, 2018, Licensee entered into an Interim Stipulated Order to voluntarily cease initiating chronic pain treatment except for patients enrolled in hospice or receiving end of life care; taper current patients to 90 MED or less or transfer care of the patient; limit prescribing for acute pain; taper concurrent benzodiazepines or transfer care of the patient; cease prescribing concurrent benzodiazepines or muscle relaxants with opioids; and obtain an EKG on all patients taking methadone at least once annually pending the completion of the Board's investigation into his ability to safely and competently practice medicine.

Junkins, Edward Paul, II, MD; MD162985; Lebanon, OR

On December 3, 2018, the Board issued an Order Terminating Consent Agreement for Re-Entry to Practice. This Order terminates Licensee's April 23, 2018, Consent Agreement for Re-Entry to Practice.

*Shilland, Eric William, DO; DO27920; Portland, OR

On November 26, 2018, Licensee entered into an Interim Stipulated Order to voluntarily cease initiating chronic pain treatment; cease initiating treatment for substance use disorder with any scheduled medications; cease writing new prescriptions for buprenorphine or buprenorphine/naloxone; taper current patients to 90 MED or less or transfer care of the

patient except for patients currently taking buprenorphine or buprenorphine/naloxone; limit prescribing for acute pain; for patients taking buprenorphine or buprenorphine/naloxone, cease initiating treatment with benzodiazepines and wean current patients off benzodiazepines within 120 days or transfer care; taper concurrent benzodiazepines or transfer care of the patient; cease prescribing concurrent benzodiazepines or muscle relaxants with opioids; and obtain an EKG on all patients taking methadone at least once annually pending the completion of the Board's investigation into his ability to safely and competently practice medicine.

*Silverman, Burton Lawrence, MD; MD19465; Beaverton, OR

On November 30, 2018, Licensee entered into an Interim Stipulated Order to voluntarily cease initiating chronic pain treatment with opioids; taper current patients to 90 MED or less or transfer care of the patient; limit prescribing for acute pain; taper concurrent benzodiazepines or transfer care of the patient; cease prescribing concurrent benzodiazepines or muscle relaxants with opioids; and obtain an EKG on all patients taking methadone at least once annually pending the completion of the Board's investigation into his ability to safely and competently practice medicine.

If you have any questions regarding this service, please call the Board at (971) 673-2700 or toll-free within Oregon at (877) 254-6263.

1	BEFORE THE	11.1
2	OREGON MEDICAL BOARD	
3.	STATE OF OREGON	
4	In the Matter of)	•
5) BEN HAROLD DOUGLAS, II, MD) INTERIM STIPULATED ORDER	
6	LICENSE NO. MD19528	
7)	
8	. 1.	
9	The Oregon Medical Board (Board) is the state agency responsible for licensing,	
10	regulating and disciplining certain health care providers, including physicians, in the state of	\mathbf{f}
11	Oregon. Ben Harold Douglas, II, MD (Licensee) is a licensed physician in the State of Ore	gon
12	and holds an active medical license.	
13	2.	
14	The Board received credible information regarding Licensee that resulted in the Board	ard
15	initiating an investigation. The results of the Board's investigation to date have raised conc	erns
6	to the extent that the Board believes it necessary that Licensee agree to certain terms until the	he
7	investigation is completed.	
8	3.	
9	In order to address the Board's concerns, Licensee and the Board agree to the entry	o <u>f</u>
20	this Interim Stipulated Order, which is not an admission of any wrongdoing on the part of the	he
11	Licensee, and will remain in effect while this matter remains under investigation, and provi-	des
22	that Licensee shall comply with the following conditions:	
23	3.1 Licensee must not begin treatment for chronic pain with opioids for any new	/or
	existing patient, unless the patient is enrolled in hospice or is receiving end of life care. If t	his
24	exception applies, Licensee must certify on any written prescription for opioids that the pat	ient is
15	a hospice patient or receiving end of life care. For the purposes of this Order, chronic pain	is
6	defined as pain that percists or progresses over a period of time; greater than 30 days.	

1	3.2 Licensee must immediately begin to taper opioid medications for any chronic pair
2	patient with a morphine equivalent dose (MED) over 90 by at least 10% per month until patient?
3	MED is 90 or less. Licensee may elect to transfer the care of any patient with an MED over 90
4	to another physician.
5	3.3 Licensee may treat patients for acute pain for no more than 30 days per year, with
6	a maximum MED of 50.
7	3.4 For patients taking benzodiazepines and opioids, Licensee must begin to taper
8	benzodiazepines after opioids have been tapered to 90 MED or less. Benzodiazepines must be
9	tapered by at least 10% per month until the patient is weaned off benzodiazepines. Alternatively
10	Licensee may transfer the care of any patient for whom he is prescribing benzodiazepines and
Ĥ	opioids to another physician. Licensee may continue to prescribe benzodiazepines to patients
12	who are enrolled in hospice or who are receiving end of life care. Licensee must certify on the
13	written prescription that the patient is a hospice patient or receiving end of life care.
14	3.5 Licensee must not concomitantly prescribe opioids with benzodiazepines
15	following tapering as outline in terms 3.2 and 3.4.
16	3.6 Licensee must not concomitantly prescribe opioids with muscle relaxants.
17	3.7 Licensee must obtain an EKG on all patients taking methadone at least once
18	annually.
19	3.8 Licensee understands that violating any term of this Order will be grounds for
20	disciplinary action under ORS 677.190(17).
21	3.9 Licensee understands this Order becomes effective the date he signs it.
22	4.
23	At the conclusion of the Board's investigation, the Board will decide whether to close the
24	case or to proceed to some form of disciplinary action. If the Board determines, following that
24	review, not to lift the requirements of this Order, Licensee may request a hearing to contest that
25	decision.
26	111

1	51.	
2	This order is issued by the Board pursuant to ORS 677.410, which grants the	Board the
3	authority to attach conditions to a Licensee's license to practice medicine. These con	iditions wil
4	remain in effect while the Board conducts a complete investigation in order to fully i	nform itsel
5	with respect to the conduct of Licensee. Pursuant to ORS 677.425, Board investigati	ive material
6	are confidential and shall not be subject to public disclosure, nor shall they be admis-	sible as
7	evidence in any judicial proceeding. However, as a stipulation this Order is a public	document
8	is reportable to the National Practitioner Databank and the Federation of State Medic	al Boards.
9)
10	IT IS SO STIPULATED THIS 20 Hay of Movember, 2018.	•
11	11 is so stipolated this 20 day of 1000 emad, 2018.	
1,2		
13	BEN HAROLD DOUGLAS, II. MD	
14	IT IS SO ORDERED THIS 27thday of November, 2018.	
1.5	OREGON MEDICAL BOARD	·
16	State of Oregon	•
17		
18	NICOLE KRISHNASWAMI, JD INTERIM EXECUTIVE DIRECTOR	
19		.5.
20		
21		
22	·	•
23		
24		
24		
25		

26

1	BEFORE THE
2	OREGON MEDICAL BOARD
3	STATE OF OREGON
4	In the Matter of)
5) ERIC WILLIAM SHILLAND, DO) INTERIM STIPULATED ORDER
6	LICENSE NO. DO27920
7	,
8	1,
9	The Oregon Medical Board (Board) is the state agency responsible for licensing,
10	regulating and disciplining certain health care providers, including physicians, in the state of
11	Oregon. Eric William Shilland, DO (Licensee) is a licensed physician in the State of Oregon and
12	holds an active medical license.
13	2,
14	The Board received credible information regarding Licensee that resulted in the Board
15	initiating an investigation. The results of the Board's investigation to date have raised concerns
16	to the extent that the Board believes it necessary that Licensee agree to certain terms until the
17	investigation is completed.
18	3.
19	In order to address the Board's concerns, Licensee and the Board agree to the entry of
20	this Interim Stipulated Order, which is not an admission of any wrongdoing on the part of the
21	Licensee. This Order will remain in effect while this matter remains under investigation, and
22	provides that Licensee shall comply with the following conditions:
23	3.1 Licensee must not begin treatment for chronic pain with opioids for any new or
24	existing patient. For the purposes of this Order, chronic pain is defined as pain that persists or
24	progresses over a period of time greater than 30 days.
25	3.2 Licensee must not begin treatment for substance use disorder with any scheduled
26	medications for any new or existing patient.

3.3 Licensee may continue to prescribe buprenorphine or buprenorphine/naloxone to any current patient taking the medication. Licensee may not begin prescribing these medications to any current patient who is not already taking the medications.

- Jicensee must immediately begin to taper opioid medications for any chronic pain patient with a morphine equivalent dose (MED) over 90 by at least 10% per month until patient's MED is 90 or less unless the patient is currently enrolled in hospice or is currently receiving end of life care. If this exception applies, Licensee must certify on the written prescription that the patient is a hospice patient or receiving end of life care. Licensee may elect to transfer the care of any patient with an MED over 90 to another physician.
- 3.5 For patients taking buprenorphine or buprenorphine/naloxone, Licensee may continue to prescribe above 90 MED, but may not increase the current dosage.
- 3.6 Licensee may treat patients for acute pain for no more than 30 days per year, with a maximum MED of 50,
- 3.7 Licensee must not begin treatment with benzodiazepines for patients taking buprenorphine or buprenorphine/naloxone.
- 3.8 For existing patients taking benzodiazepines with buprenorphine, or benzodiazepines with buprenorphine/naloxone, Licensee must wean the patient off benzodiazepines within 120 days. Alternatively, Licensee may transfer the care of any patient for whom he is prescribing benzodiazepines and opioids to another physician.
- 3.9 For patients taking benzodiazepines and opioids (other than buprenorphine or buprenorphine/naloxone), Licensee must begin to taper benzodiazepines after opioids have been tapered to 90 MED or less. Benzodiazepines must be tapered by at least 10% per month until the patient is weaned off benzodiazepines. Alternatively, Licensee may transfer the care of any patient for whom he is prescribing benzodiazepines and opioids to another physician. Licensee may continue to prescribe concurrent benzodiazepines to patients who are currently enrolled in hospice or who are currently receiving end of life care. Licensee must certify on the written prescription that the patient is a hospice patient or receiving end of life care.

1	3.10 Licensee must not concomitantly prescribe opioids with benzodiazepines
2	following tapering as outlined in terms 3.4 and 3.8.
3	3.11 Licensee must not concomitantly prescribe opioids with muscle relaxants.
4	3.12 Licensee must obtain an EKG on all patients taking methadone at least once
5	annually.
6	3.13 Licensee understands that violating any term of this Order will be grounds for
7	disciplinary action under ORS 677.190(17).
8	3.14 Licensee understands this Order becomes effective the date he signs it.
9	4.
10	At the conclusion of the Board's investigation, the Board will decide whether to close the
11	case or to proceed to some form of disciplinary action. If the Board determines, following that
12	review, not to lift the requirements of this Order, Licensee may request a hearing to contest that
13	decision,
14	5,
15	This order is issued by the Board pursuant to ORS 677.410, which grants the Board the
16	authority to attach conditions to Licensee's license to practice medicine. These conditions will
17	remain in effect while the Board conducts a complete investigation in order to fully inform itself
18	with respect to the conduct of Licensee. Pursuant to ORS 677.425, Board investigative
19	///
20	///
21	111
22	111
23	///
24	<i>111.</i>
24	. 111
25	
26	///

Page 3 - INTERIM STIPULATED ORDER - Eric William Shilland, DO

1	materials are confidential and shall not be subject to public disclosure, nor shall they be admissible
2	as evidence in any judicial proceeding. However, as a stipulation this Order is a public document
3	and is reportable to the National Databank and the Federation of State Medical Boards.
4	
5	IT IS SO STIPULATED THIS 26 day of November, 2018.
6	THIS SO STIPULATED THIS CO day of 14000100, 2018.
7	ERIC WILLIAM SHILLAND, DO
8	
9	IT IS SO ORDERED THIS 27 Holay of November, 2018.
10	OREGON MEDICAL BOARD
11	State of Oregon
12	
13	NICOLE KRISHNASWAMI, JD EXECUTIVE DIRECTOR
14	, EXECUTAL DIRECTOR
15	· •
16	
17	
18	
19	
20	
21	
22	
23	•
24	
24	
25	
26	

1	BEFORE THE
2 ·	OREGON MEDICAL BOARD
3	STATE OF OREGON
4	In the Matter of)
5	BURTON LAWRENCE SILVERMAN, MD) INTERIM STIPULATED ORDER
6	LICENSE NO. MD19465
7	
8	1.
9.	The Oregon Medical Board (Board) is the state agency responsible for licensing,
10	regulating and disciplining certain health care providers, including physicians, in the state of
11	Oregon. Burton Lawrence Silverman, MD (Licensee) is a licensed physician in the State of
12	Oregon and holds an active medical license.
13	2.
14	The Board received credible information regarding Licensee that resulted in the Board
15	initiating an investigation. The results of the Board's investigation to date have raised concerns
16	to the extent that the Board believes it necessary that Licensee agree to certain terms until the
17	investigation is completed.
18	3.
19	In order to address the Board's concerns, Licensee and the Board agree to the entry of
20	this Interim Stipulated Order, which is not an admission of any wrongdoing on the part of the
21	Licensee. This Order will remain in effect while this matter remains under investigation, and
22	provides that Licensee shall comply with the following conditions:
23	3.1 Licensee must not begin treatment for chronic pain with opioids for any new or
24	existing patient. For the purposes of this Order, chronic pain is defined as pain that persists or
24	progresses over a period of time greater than 30 days.
25	3.2 Licensee must immediately begin to taper opioid medications for any chronic pair
26	patient with a morphine equivalent dose (MED) over 90 by at least 10% per month until patient's

Page 1 - INTERIM STIPULATED ORDER - Burton Lawrence Silverman, MD

l	MED is 90 or less, unless the patient is enrolled in hospice or is receiving end of life care. If this
2 ·	exception applies, Licensee must certify on the written prescription that the patient is a hospice
3	patient or is receiving end of life care. Licensee may elect to transfer the care of any patient with
4	an MED over 90 to another physician.
5	3.3 Licensee may treat patients for acute pain for no more than 30 days per year, with
6	a maximum MED of 50.
7	3.4 For patients taking benzodiazepines and opioids, Licensee must begin to taper
8	benzodiazepines after opioids have been tapered to 90 MED or less. Benzodiazepines must be
9	tapered by at least 10% per month until the patient is weaned off benzodiazepines. Alternatively,
10	Licensee may transfer the care of any patient for whom he is prescribing benzodiazepines and
11	opioids to another physician. Licensee may continue to prescribe benzodiazepines to patients
12	who are enrolled in hospice or who are receiving end of life care. Licensee must certify on the
13	written prescription that the patient is a hospice patient or receiving end of life care.
14	3.5 Licensee must not concomitantly prescribe opioids with benzodiazepines
15	following tapering as outlined in terms 3.2 and 3.4.
16	3.6 Licensee must not concomitantly prescribe opioids with muscle relaxants.
17	3.7 Licensee must obtain an EKG on all patients taking methadone at least once
18	annually.
19	3.8 Licensee understands that violating any term of this Order will be grounds for
20	disciplinary action under ORS 677.190(17).
21	3.9 Licensee understands this Order becomes effective the date he signs it.
22	4.
23	At the conclusion of the Board's investigation, the Board will decide whether to close the
24	case or to proceed to some form of disciplinary action. If the Board determines, following that
24	review, not to lift the requirements of this Order, Licensee may request a hearing to contest that
25	decision.
26	

Page 2 - INTERIM STIPULATED ORDER - Burton Lawrence Silverman, MD

5. 2 · This order is issued by the Board pursuant to ORS 677.410, which grants the Board the authority to attach conditions to Licensee's license to practice medicine. These conditions will remain in effect while the Board conducts a complete investigation in order to fully inform itself with respect to the conduct of Licensee. Pursuant to ORS 677.425, Board investigative materials are confidential and shall not be subject to public disclosure, nor shall they be admissible as evidence in any judicial proceeding. However, as a stipulation this Order is a public document and is reportable to the National Practitioner Databank and the Federation of State Medical Boards. IT IS SO STIPULATED THIS 30 day of Movemels, 2018. BURTON LAWRENCE SILVERMAN, MD IT IS SO ORDERED THIS 30 Holav of 1 OREGON MEDICAL BOARD State of Oregon. NICOLE KRISHNASWAMI, JD EXECUTIVE DIRECTOR